- Home
- ALPN
as 05-20-2024 4:00pm EST
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 4.2B | IPO Year: | N/A |
| Target Price: | $52.29 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.33 - $65.00 | Next Earning Date: | 05-09-2024 |
| Revenue: | $56,521,000 | Revenue Growth: | 118.89% |
| Revenue Growth (this year): | -72.93% | Revenue Growth (next year): | 4.48% |
Share on Social Networks:
Stock Insider Trading Activity of Alpine Immune Sciences Inc. (ALPN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Topper James N | ALPN | Director | Apr 25 '24 | Sell | $64.57 | 19 | $1,226.83 | 2,829,347 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 28 '23 | Sell | $20.04 | 1,016 | $20,361.96 | 0 | SEC Form 4 |
| ORBIMED ADVISORS LLC | ALPN | Director | Dec 27 '23 | Sell | $18.32 | 139,166 | $2,549,521.12 | 264,315 | SEC Form 4 |
| ORBIMED ADVISORS LLC | ALPN | Director | Dec 27 '23 | Sell | $18.32 | 1,195,683 | $21,904,912.56 | 2,270,930 | SEC Form 4 |
| ORBIMED ADVISORS LLC | ALPN | Director | Dec 27 '23 | Sell | $19.82 | 3,128 | $61,996.96 | 403,481 | SEC Form 4 |
| ORBIMED ADVISORS LLC | ALPN | Director | Dec 27 '23 | Sell | $19.82 | 26,872 | $532,603.04 | 3,466,613 | SEC Form 4 |
| ORBIMED ADVISORS LLC | ALPN | Director | Dec 27 '23 | Sell | $19.96 | 18,922 | $377,683.12 | 406,609 | SEC Form 4 |
| ORBIMED ADVISORS LLC | ALPN | Director | Dec 27 '23 | Sell | $19.96 | 162,576 | $3,245,016.96 | 3,493,485 | SEC Form 4 |
| Thompson Peter A. | ALPN | Director | Dec 27 '23 | Sell | $19.96 | 162,576 | $3,245,016.96 | 3,493,485 | SEC Form 4 |
| Thompson Peter A. | ALPN | Director | Dec 27 '23 | Sell | $19.96 | 18,922 | $377,683.12 | 406,609 | SEC Form 4 |
| Thompson Peter A. | ALPN | Director | Dec 27 '23 | Sell | $19.82 | 26,872 | $532,603.04 | 3,466,613 | SEC Form 4 |
| Thompson Peter A. | ALPN | Director | Dec 27 '23 | Sell | $19.82 | 3,128 | $61,996.96 | 403,481 | SEC Form 4 |
| Thompson Peter A. | ALPN | Director | Dec 27 '23 | Sell | $18.32 | 1,195,683 | $21,904,912.56 | 2,270,930 | SEC Form 4 |
| Thompson Peter A. | ALPN | Director | Dec 27 '23 | Sell | $18.32 | 139,166 | $2,549,521.12 | 264,315 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 22 '23 | Sell | $20.04 | 29,573 | $592,716.85 | 0 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 22 '23 | Sell | $20.22 | 24,486 | $495,217.11 | 0 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 22 '23 | Sell | $20.43 | 37,825 | $772,594.54 | 0 | SEC Form 4 |
| Rickey James Paul | ALPN | See Remarks | Dec 19 '23 | Sell | $19.21 | 15,213 | $292,221.95 | 0 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 19 '23 | Sell | $20.01 | 2,402 | $48,063.78 | 0 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 8 '23 | Sell | $17.08 | 8,067 | $137,783.55 | 101,320 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 8 '23 | Sell | $17.26 | 68,870 | $1,189,026.78 | 32,450 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 8 '23 | Sell | $17.32 | 32,450 | $561,887.98 | 0 | SEC Form 4 |
| GOLD MITCHELL | ALPN | Executive Chairman and CEO | Dec 8 '23 | Sell | $17.32 | 8,613 | $149,138.40 | 0 | SEC Form 4 |
| Rickey James Paul | ALPN | See Remarks | Dec 4 '23 | Sell | $16.06 | 63,947 | $1,026,886.50 | 0 | SEC Form 4 |
| Rickey James Paul | ALPN | See Remarks | Dec 4 '23 | Sell | $16.01 | 418 | $6,693.81 | 0 | SEC Form 4 |
Latest Alpine Immune Sciences Inc. News
ALPN Breaking Stock News: Dive into ALPN Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone
GuruFocus.com
10 days ago
Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...
Business Wire
11 days ago
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
Insider Monkey
13 days ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript
Thomson Reuters StreetEvents
13 days ago
Q1 2024 Vertex Pharmaceuticals Inc Earnings Call
GuruFocus.com
14 days ago
Vertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
Motley Fool
14 days ago
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
Zacks
18 days ago